These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32949947)

  • 1. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
    Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
    Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
    Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
    Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups.
    Goyal S; Tanigawa Y; Zhang W; Chai JF; Almeida M; Sim X; Lerner M; Chainakul J; Ramiu JG; Seraphin C; Apple B; Vaughan A; Muniu J; Peralta J; Lehman DM; Ralhan S; Wander GS; Singh JR; Mehra NK; Sidorov E; Peyton MD; Blackett PR; Curran JE; Tai ES; van Dam R; Cheng CY; Duggirala R; Blangero J; Chambers JC; Sabanayagam C; Kooner JS; Rivas MA; Aston CE; Sanghera DK
    Lipids Health Dis; 2021 Sep; 20(1):113. PubMed ID: 34548093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics.
    Chan DC; Watts GF; Nguyen MN; Barrett PH
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):590-6. PubMed ID: 16410456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
    Zheng C; Khoo C; Furtado J; Sacks FM
    Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.
    Campos H; Perlov D; Khoo C; Sacks FM
    J Lipid Res; 2001 Aug; 42(8):1239-49. PubMed ID: 11483625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease.
    Mendivil CO; Rimm EB; Furtado J; Chiuve SE; Sacks FM
    Circulation; 2011 Nov; 124(19):2065-72. PubMed ID: 21986282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 9. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration.
    Chan DC; Watts GF; Redgrave TG; Mori TA; Barrett PH
    Metabolism; 2002 Aug; 51(8):1041-6. PubMed ID: 12145779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
    Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins.
    Furtado JD; Wedel MK; Sacks FM
    J Lipid Res; 2012 Apr; 53(4):784-91. PubMed ID: 22301884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.
    Ooi EM; Chan DT; Watts GF; Chan DC; Ng TW; Dogra GK; Irish AB; Barrett PH
    J Lipid Res; 2011 Apr; 52(4):794-800. PubMed ID: 21297177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome.
    Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH
    Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.
    Conde-Knape K; Okada K; Ramakrishnan R; Shachter NS
    J Lipid Res; 2004 Dec; 45(12):2235-44. PubMed ID: 15342689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
    Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
    Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.
    Mendivil CO; Rimm EB; Furtado J; Sacks FM
    J Am Heart Assoc; 2013 May; 2(3):e000130. PubMed ID: 23672999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
    Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
    J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.